Gilead, Teva Cleared of Pay-to-Delay HIV Drug Antitrust Claims (1)

A California jury found that Gilead Sciences Inc. and Teva Pharmaceutical Industries Ltd. didn’t engage in an anticompetitive conspiracy to delay generic versions of HIV treatment Truvada and other drugs.

The unanimous verdict Friday from the US District Court for the Northern District of California affirmed that a 2014 patent settlement between Foster City, Calif.-based Gilead and Israel-based Teva didn’t violate antitrust law.

Consumers and other direct purchasers, including the Blue Cross and Blue Shield Association, filed the antitrust lawsuit in 2019, alleging that Gilead maintained a monopoly in the HIV drug market by unlawfully extending patent protection for its ...